– IRELAND – Marvao Medical Devices Limited today announces that medical technology industry leader Eamonn P. Hobbs has been appointed Chairman of the Company’s Board of Directors. Mr Hobbs replaces former Board Chairman John Burns, who will continue to serve as a member of the Board.
“Eamonn Hobbs is both an industry thought leader and a proven builder of successful organizations,” said Chris Davey, Co-Founder and CEO of Marvao. “He brings to Marvao a wealth of clinical, regulatory, operational and commercial contacts and leadership experiences which will benefit both our Board as well as our entire company. We look forward to working with him as Marvao further develops its NexSite™ product line.” Mr Davey continued, “In welcoming Eamonn, our Board would also like to thank John Burns for his outstanding leadership as our chairman over the last five years, and we look forward to his continued dedicated service as a Marvao director moving forward.”
“Marvao has reached an inflection point in its corporate development, and the invitation to join the Board of Directors and serve as chairman was quite compelling,” said Mr Hobbs. “The company’s recent FDA clearance for a dialysis catheter product line utilizing Marvao’s NexSite™ technology is an important milestone from which the Company can commence commercialization and develop additional NexSite product lines.”
A dual citizen of Ireland and the United States, Mr Hobbs brings to Marvao more than 30 years of leadership experience in a number of medical technology industry segments including interventional radiology, oncology, interventional cardiology, surgery, gastroenterology and medical device/pharmaceutical combination products. After graduating from the University of Massachusetts-Lowell in 1980 with a degree in Plastics Engineering, Mr Hobbs immediately went to work as a Product Development Engineer with Cook Incorporated. He co-founded AngioDynamics in 1988 and served as the Company’s President and CEO until 2008. During his tenure, he built the Company into a global market leader with more than $200 million in sales and 700 employees. In 2009 he transitioned from a Delcath Systems, Inc. Board of Directors member to President and CEO and served as Chairman on the Medical Device Manufacturers Association (MDMA) Board of Directors from 2010 to 2013.
In addition to Marvao, Mr Hobbs also is Chairman of the Board of Morris Innovative, Inc., and is a member of the Board of Directors of Antares Pharmaceuticals (NASDAQ: ATRS); Harmonic Medical, Inc. the MDMA and the Glens Falls (NY) Hospital.
About NexSite™ ESMTM
Many types of catheters exit the patient’s body through an open wound in the skin. Effective management of the catheter exit site using antibiotic ointments or antimicrobial dressings has been shown to reduce the risk of catheter related bloodstream infection (CRBSI) associated with these catheters. Marvao Medical’s innovative NexSite™ ESM™ technology is a novel technology for the management of the catheter exit site. It is based on tissue ingrowth and features our patented DISC™ (Dermal Ingrowth Support Collar) that enables the wound in the skin at the catheter exit site to heal. Marvao Medical is working to incorporate NexSite™ ESM™ technology on a broad range of long term implantable medical devices.
About Marvao Medical
Marvao Medical specializes in the development, manufacturing and marketing of innovative medical devices to address unmet clinical needs and deliver high quality of care to the patient population.
Based at the Innovation in Business Centre on the Galway Mayo Institute of Technology campus, Marvao Medical is supported by investments from Enterprise Ireland, the Western Development Commission, Enterprise Equity and private investors. Marvao Medical has partnered with Harmac Medical Products (Castlerea, Roscommon) to manufacture NexSite catheter products.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.